Spruce Biosciences Common Stock Performance

SPRB Stock  USD 77.55  2.31  2.89%   
The entity has a beta of 0.16, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Spruce Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Spruce Biosciences is expected to be smaller as well. At this point, Spruce Biosciences Common has a negative expected return of -0.31%. Please make sure to validate Spruce Biosciences' kurtosis, as well as the relationship between the day median price and period momentum indicator , to decide if Spruce Biosciences Common performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Spruce Biosciences Common has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more

Actual Historical Performance (%)

One Day Return
(2.89)
Five Day Return
(3.15)
Year To Date Return
(14.50)
Ten Year Return
(93.92)
All Time Return
(93.92)
Last Split Factor
1:75
Last Split Date
2025-08-07
1
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - BioSpace
11/10/2025
2
Disposition of 1196 shares by Szwarcberg Javier B. of Spruce Biosciences, subject to Rule 16b-3
12/10/2025
3
Disposition of 2194 shares by Szwarcberg Javier B. of Spruce Biosciences, at 88.41 subject to Rule 16b-3
12/11/2025
4
This Levi Strauss Analyst Begins Coverage On A Bullish Note Here Are Top 5 Initiations For Tuesday
12/23/2025
5
Acquisition by Szwarcberg Javier B. of 4690 shares of Spruce Biosciences at 4.5305 subject to Rule 16b-3
12/31/2025
6
Spruce Biosciences Secures Up to 50 Million in Growth Capital from Avenue Capital
01/08/2026
7
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium
01/28/2026

Spruce Biosciences Relative Risk vs. Return Landscape

If you would invest  10,494  in Spruce Biosciences Common on November 4, 2025 and sell it today you would lose (2,739) from holding Spruce Biosciences Common or give up 26.1% of portfolio value over 90 days. Spruce Biosciences Common is currently does not generate positive expected returns and assumes 6.1997% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Spruce, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Spruce Biosciences is expected to under-perform the market. In addition to that, the company is 8.34 times more volatile than its market benchmark. It trades about -0.05 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.09 per unit of volatility.

Spruce Biosciences Target Price Odds to finish over Current Price

The tendency of Spruce Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 77.55 90 days 77.55 
about 83.47
Based on a normal probability distribution, the odds of Spruce Biosciences to move above the current price in 90 days from now is about 83.47 (This Spruce Biosciences Common probability density function shows the probability of Spruce Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Spruce Biosciences has a beta of 0.16. This usually implies as returns on the market go up, Spruce Biosciences average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Spruce Biosciences Common will be expected to be much smaller as well. Additionally Spruce Biosciences Common has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Spruce Biosciences Price Density   
       Price  

Predictive Modules for Spruce Biosciences

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Spruce Biosciences Common. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
71.4077.5583.70
Details
Intrinsic
Valuation
LowRealHigh
68.1074.2580.40
Details
Naive
Forecast
LowNextHigh
76.3582.5088.65
Details
5 Analysts
Consensus
LowTargetHigh
209.76230.50255.86
Details

Spruce Biosciences Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Spruce Biosciences is not an exception. The market had few large corrections towards the Spruce Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Spruce Biosciences Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Spruce Biosciences within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.53
β
Beta against Dow Jones0.16
σ
Overall volatility
15.48
Ir
Information ratio -0.09

Spruce Biosciences Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Spruce Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Spruce Biosciences Common can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Spruce Biosciences generated a negative expected return over the last 90 days
Spruce Biosciences has high historical volatility and very poor performance
The company reported the previous year's revenue of 4.91 M. Net Loss for the year was (53.04 M) with loss before overhead, payroll, taxes, and interest of (36.18 M).
Spruce Biosciences Common currently holds about 93.3 M in cash with (55.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96.
Latest headline from finance.yahoo.com: Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium

Spruce Biosciences Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Spruce Stock often depends not only on the future outlook of the current and potential Spruce Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Spruce Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding536.4 K
Cash And Short Term Investments38.8 M

Spruce Biosciences Fundamentals Growth

Spruce Stock prices reflect investors' perceptions of the future prospects and financial health of Spruce Biosciences, and Spruce Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Spruce Stock performance.

About Spruce Biosciences Performance

By analyzing Spruce Biosciences' fundamental ratios, stakeholders can gain valuable insights into Spruce Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Spruce Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Spruce Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(1.06)(1.11)
Return On Capital Employed(1.69)(1.77)
Return On Assets(1.06)(1.11)
Return On Equity(2.12)(2.01)

Things to note about Spruce Biosciences Common performance evaluation

Checking the ongoing alerts about Spruce Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Spruce Biosciences Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Spruce Biosciences generated a negative expected return over the last 90 days
Spruce Biosciences has high historical volatility and very poor performance
The company reported the previous year's revenue of 4.91 M. Net Loss for the year was (53.04 M) with loss before overhead, payroll, taxes, and interest of (36.18 M).
Spruce Biosciences Common currently holds about 93.3 M in cash with (55.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96.
Latest headline from finance.yahoo.com: Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium
Evaluating Spruce Biosciences' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Spruce Biosciences' stock performance include:
  • Analyzing Spruce Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Spruce Biosciences' stock is overvalued or undervalued compared to its peers.
  • Examining Spruce Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Spruce Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Spruce Biosciences' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Spruce Biosciences' stock. These opinions can provide insight into Spruce Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Spruce Biosciences' stock performance is not an exact science, and many factors can impact Spruce Biosciences' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Spruce Stock analysis

When running Spruce Biosciences' price analysis, check to measure Spruce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spruce Biosciences is operating at the current time. Most of Spruce Biosciences' value examination focuses on studying past and present price action to predict the probability of Spruce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spruce Biosciences' price. Additionally, you may evaluate how the addition of Spruce Biosciences to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume